- Home
- ELLO vs CRVS Comparison
ELLO vs CRVS Comparison
Compare ELLO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELLO | CRVS |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.9M | 634.0M |
| IPO Year | 1995 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ELLO | CRVS |
|---|---|---|
| Price | $21.85 | $8.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 3.7K | ★ 1.0M |
| Earning Date | 12-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,322,959.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.00 | $2.54 |
| 52 Week High | $23.95 | $9.60 |
Technical Indicators
Market Signals| Indicator | ELLO | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 51.32 |
| Support Level | $21.82 | $8.31 |
| Resistance Level | $23.95 | $9.60 |
| Average True Range (ATR) | 0.81 | 0.54 |
| MACD | 0.12 | -0.09 |
| Stochastic Oscillator | 60.32 | 26.75 |
Price Performance
Historical ComparisonAbout ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).